A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Phase 1 Withdrawn
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
431 enrolled
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1 Completed
29 enrolled
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
41 enrolled
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Phase 1 Completed
37 enrolled
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Phase 1 Completed
98 enrolled
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
Phase 1 Completed
16 enrolled
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase 1 Completed
45 enrolled
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Phase 1 Completed
41 enrolled
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
Phase 1 Completed
34 enrolled
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
Phase 1 Completed
45 enrolled
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
Phase 1 Completed
9 enrolled
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
Phase 1 Completed
47 enrolled
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Phase 1 Completed
107 enrolled
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled